Balancing the cost and value of medications: The dilemma facing clinicians

PharmacoEconomics

Volumn 20, Issue SUPPL. 3, 2002, Pages 67-72

  Avorn, Jerry ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BUDGET; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CURRICULUM; DOCTOR PATIENT RELATION; DRUG CLASSIFICATION; DRUG COST; DRUG FORMULARY; EDUCATION PROGRAM; EXPERT SYSTEM; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RESIDENCY EDUCATION; RISK ASSESSMENT;

EID: 0036439649     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220003-00006     Document Type: Conference Paper

References (7)

1. Avorn J. The prescription as final common pathway. Int J Technol Assess Health Care 1995; 11 (3): 384-90
2. Colowick AB, Bohn RL, Avorn J, et al. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper. Blood 2000; 96: 1698-702
3. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: A randomized controlled trial of academically based 'detailing'. N Engl J Med 1983; 308: 1457-63
4. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992; 327: 168-73
5. Solomon DH, van Houten L, Glynn RJ, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med 2001; 161: 1897-902
6. Schneeweiss SB, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002; 346 (11): 822-9
7. Knight EL, Avorn J. Quality indicators for appropriate medication use in the care of the vulnerable elderly. Ann Intern Med 2001; 135: 703-10